Poop pills for cancer patients? pilot study tests fecal transplants in High-Risk therapies

NCT ID NCT07509450

Recruiting now Knowledge-focused Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 2 times

Summary

This pilot study is testing whether fecal microbiota transplantation (FMT) — giving processed stool from a healthy donor via enema — is safe and doable in 20 patients with lymphoma or leukemia who are receiving CAR-T therapy or stem cell transplants. The goal is to see if at least half of approached patients join, most stay in the study, and the procedure doesn't cause serious harm. It's an early step to explore if restoring gut bacteria can help these vulnerable patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Fecal microbiota transplant (FMT) enema
What this could lead to: If successful, this could show that FMT is a safe way to restore gut health in patients undergoing intensive cancer therapies, potentially reducing complications.
What could go wrong: This is a very small pilot study with only 20 participants, so results may not apply broadly. There is a risk of serious side effects like infection or bowel injury from the procedure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia B-cell neoplasm B-cell non-Hodgkin lymphoma myelodysplastic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LYMPHOMA RECEIVING CAR-T THERAPY

Contacts and locations

Locations

University Health Network
RECRUITING

Toronto, Ontario, M5G 2M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.